VIRPAX PHARMACEUTICALS INC (VRPX) Stock Income Statement
USA - NASDAQ:VRPX - US9282512063 - Common Stock
0.6695 USD
-0.55 (-45.12%)
0.4498 USD
-0.22 (-32.82%)
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | |||
| Gross Premiums Earned | null | null | null | null | null | |||
| Loss Claims | null | null | null | null | null | |||
| Deferred Policy Acquisition Expense | null | null | null | null | null | |||
| Net Interest Income | null | null | null | null | null | |||
| Non Interest Income | null | null | null | null | null | |||
| Loan Loss Provision | null | null | null | null | null | |||
| Net Interest Income after Provision | null | null | null | null | null | |||
| Non Interest Expense | null | null | null | null | null | |||
| Minority Interest Expense | null | null | null | null | null | |||
| Cost Of Goods | null | null | null | null | null | |||
| Gross Profit | null | null | null | null | null | |||
| Operating Expenses | 12.08M | 15.69M | 21.85M | 12.03M | 4.20M | |||
| Research and Development | 5.82M | 5.12M | 10.76M | 4.84M | 1.29M | |||
| Selling, General, and Administrative Expenses | 6.26M | 10.57M | 11.08M | 7.19M | 2.90M | |||
| Operating Income | -12.08M | -15.69M | -21.85M | -12.03M | -4.20M | |||
| Interest Income/Expense | -103.80K | null | 0 | -92.80K | -147.90K | |||
| Other Income/Expense | 116.50K | 500.30K | 194.40K | 62.30K | 4.00K | |||
| Non Recurring Items | null | null | null | null | null | |||
| Income Before Taxes | -12.07M | -15.19M | -21.65M | -12.06M | -4.34M | |||
| Income Tax | null | 0 | 0 | 0 | 0 | |||
| Net Income | -12.07M | -15.19M | -21.65M | -12.06M | -4.34M | |||
| EBITDA | undefined | undefined | undefined | undefined | undefined | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -2.8364 | -12.97 | -18.49 | -18.06 | -8.78 | |||
| Non GAAP EPS | null | null | null | null | null | |||
| Statistics | ||||||||
All data in USD